EBV-Associated Lymphoma Consortium Annual Meeting (Abstract)

Abstract Submission

Submission information

Submission Number: 1

Submission ID: 149570

Submission UUID: 4c14a1c5-4121-44d7-8592-4f5bb9ae7215

Submission URI: /nci/ealv/venue/abstract

Submission Update: /nci/ealv/venue/abstract?token=myybJyZojBOECcTKY3Fa7ur3-ilgmhHsNuM_jM4TQFM

Created: Sat, 08/23/2025 - 05:15

Completed: Sat, 08/23/2025 - 05:15

Changed: Sat, 08/23/2025 - 05:15

Remote IP address: 10.208.28.6

Submitted by: Anonymous

Language: English

Is draft: No

Webform: EBV-Associated Lymphoma Consortium Annual Meeting (Abstracts)

Submitted to: EBV-Associated Lymphoma Consortium Annual Meeting (Abstract)

OMB No.: 0925-0740
Expiration Date: 9/30/2025

Public reporting burden for this collection of information is estimated to average 60 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0740). Do not return the completed form to this address.

Presenter Information

Please enter information for the person who will be the primary presenter/speaker/author.

First Name

Middle Initial

Last Name

Degree(s)

Please use the following formatting for these degrees: M.D. Ph.D. MPH

Position/Title/Career Status

Organization

Organization City/Town

Please provide a contact email for conference organizers to reach you.

Abstract Information

Abstract Keywords

Up to five keywords of your choice

Abstract Title

Abstract Summary

Infection of Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus-8 (HHV-8), is estimated to account for 34,000 new cancer cases each year, presenting a significant healthcare challenge globally. Typically, KSHV infection in healthy infected individuals results in weak neutralizing antibody responses and low T cell immunity. This modest immunity during natural infection calls for a vaccine that can circumvent the immune evasion mechanisms of KSHV, effectively priming the immune system to generate robust and reliable immunity across individuals. Such a vaccine would not only protect against initial infections but also help individuals maintain better control over persistent infection, thereby reducing the risk of developing KSHVassociated diseases. This is particularly vital for high-risk populations, including individuals with an increased likelihood of HIV-1 infection, transplant patients receiving immunosuppressive therapy, and people living in resource-limited endemic regions of Africa. Our proposal addresses this critical medical need.
Our proposal outlines a comprehensive and innovative vaccine strategy against KSHV, harnessing antibody and T cells to establish strong antiviral immunity. Aim 1 focuses on generating potent humoral antibody responses through structure-guided immunogen design, generating neutralizing and non-neutralizing activities that block infection and mediate the immune clearance of infected cells. Aim 2 is dedicated to enhancing vaccineinduced T cell immunity targeting latently infected cells by utilizing innovative RNA-based adjuvants. These RNA-adjuvanted T cell responses are designed to complement antibody-mediated antiviral effects. Aim 3 seeks to integrate these strategies by combining vaccine components that simulate both antibody and T cell responses while maintaining the immunogenicity of each antigen. This aim will also employ mice reconstituted with the human immune system to address species differences in terms of dendritic cell activation and inflammatory responses after receiving our combined vaccine.